Phaseline

Targets › SERPING1

SERPING1 (Plasma protease C1 inhibitor): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 3; Cardiovascular, Immunology, Genitourinary; next expected readout Dec 2026.

Serine protease inhibitor, which acrs as a regulator of the classical complement pathway. Forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. (UniProt, P05155)

Open in Phaseline: the race on SERPING1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OctapharmaOCTA-C1-INH
C1 esterase inhibitor (C1-INH) protein replacement
SERPING1Phase 3Acute Hereditary Angio EdemaDec 2026
Haaglanden Medical CentreConestat Alfa
Plasma protease C1 inhibitor exogenous protein
SERPING1Phase 2Subarachnoid Hemorrhage, AneurysmalMar 2027
National Institute of Allergy and Infectious Diseases (NIAID)Conestat Alfa
Plasma protease C1 inhibitor exogenous protein
SERPING1Phase 2Kidney TransplantMay 2031

Conditions

Subarachnoid Hemorrhage, Aneurysmal (1) Acute Hereditary Angio Edema (1) Kidney Transplant (1)

Modalities

protein or peptide (2), small molecule (1)

Companies

Haaglanden Medical Centre (1) Octapharma (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.